TREA

79282940 - DELIVEREX

Follow

Information

  • Trademark
  • 79282940
  • Serial Number
    79282940
  • Registration Number
    6405652
  • Filing Date
    January 31, 2020
    5 years ago
  • Registration Date
    July 06, 2021
    3 years ago
  • Transaction Date
    December 04, 2021
    3 years ago
  • Status Date
    July 06, 2021
    3 years ago
  • Published for Opposition Date
    April 20, 2021
    4 years ago
  • Location Date
    July 06, 2021
    3 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    PAYABYAB, EDWARD TAN
  • Attorney Name
    Bryce J. Maynard
    Law Office Assigned Location Code
    O10
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
DELIVEREX
Case File Statements
  • GS0051: Pharmaceutical preparations and substances for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered and purified exosomes in the form of a liquid solution and lyophilised preparation for therapeutic use in the nature of treatment of for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; pharmaceutical preparations, namely, exosomes to deliver protein for genetic therapy; Medicine for treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; biological preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy; mixed biological preparations for the prevention and treatment of infectious diseases; EV-based nucleic acid therapeutics in the nature of pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars, and therapeutics for the prevention and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strains and tears, ligament strains and tears, muscle atrophy, and muscular dystrophy
  • GS0441: Medical services; medical and pharmaceutical consultancy; medical services relating to the diagnosis and treatment of persons; medical analysis service relating to the diagnosis and treatment of persons provided by medical laboratories; medical analysis and examinations for the diagnosis of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, rare diseases, genetic diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; medical treatment services in the field of biotherapeutics for the treatment of infectious diseases, cancer, neurological disorders, neurodegenerative disorders, inflammatory disorders, rare diseases, genetic and metabolic disorders; medical screening; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of viral and bacterial based infections and diseases; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy
  • PM0001: DELIVER EX
Case File Event Statements
  • 12/4/2021 - 3 years ago
    36 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 11/23/2021 - 3 years ago
    35 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 11/1/2021 - 3 years ago
    34 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 11/1/2021 - 3 years ago
    33 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 10/6/2021 - 3 years ago
    32 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 7/6/2021 - 3 years ago
    31 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 5/4/2021 - 4 years ago
    30 - LIMITATION FROM THE IB EXAMINED AND ENTERED Type: LIME
  • 5/1/2021 - 4 years ago
    29 - LIMITATION OF GOODS RECEIVED FROM IB Type: LIMG
  • 4/20/2021 - 4 years ago
    28 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 4/20/2021 - 4 years ago
    27 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 4/18/2021 - 4 years ago
    26 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 3/31/2021 - 4 years ago
    25 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 3/31/2021 - 4 years ago
    24 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 3/31/2021 - 4 years ago
    23 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 3/13/2021 - 4 years ago
    22 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 3/13/2021 - 4 years ago
    21 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 3/13/2021 - 4 years ago
    20 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 3/13/2021 - 4 years ago
    19 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 3/13/2021 - 4 years ago
    18 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 3/6/2021 - 4 years ago
    17 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3
  • 3/6/2021 - 4 years ago
    16 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 3/6/2021 - 4 years ago
    15 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 1/28/2021 - 4 years ago
    14 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 1/28/2021 - 4 years ago
    13 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 1/27/2021 - 4 years ago
    12 - ASSIGNED TO LIE Type: ALIE
  • 10/16/2020 - 4 years ago
    11 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 7/30/2020 - 4 years ago
    10 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 5/29/2020 - 4 years ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 5/14/2020 - 4 years ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 5/14/2020 - 4 years ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 4/30/2020 - 5 years ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 4/29/2020 - 5 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 4/20/2020 - 5 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 4/17/2020 - 5 years ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 4/13/2020 - 5 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 4/9/2020 - 5 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR